PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

Slides:

Advertisements

Similar presentations

BRD4 is associated with poor patient survival and constitutes a promising target for NRASMut melanoma BRD4 is associated with poor patient survival and.

Advertisements

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

CHK1 downregulation upon ERG overexpression.

Microarray analysis of phospho-Twist1–responsive genes.

Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.

BRD4 is associated with poor patient survival and constitutes a promising target for NRASMut melanoma BRD4 is associated with poor patient survival and.

Volume 17, Issue 2, Pages (February 2009)

B cells infiltrate mouse and human pancreatic neoplasia and promote growth of KrasG12D-PDEC in vivo. B cells infiltrate mouse and human pancreatic neoplasia.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

SIRT1 is downregulated in human gastric cancer (GC).

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Silencing Socs1 in the LLC line confers increased response to IFNγ in vitro and in vivo. Silencing Socs1 in the LLC line confers increased response to.

Autophagy restrains pancreatic inflammation and expression of pTBK1, CCL5, and PD-L1 in vivo. Autophagy restrains pancreatic inflammation and expression.

Correlation of RSPO expression to LGR5 expansion in gastric cancer.

Increased CCL5 expression, infiltration of Treg cells, and apoptosis of CD8+ T cells in human colorectal tissues. Increased CCL5 expression, infiltration.

PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC

Effect of HA on hematopoietic recovery in tumor-bearing mice.

CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.

IL32 is highly expressed in mycosis fungoides lesional skin.

coTCRcys-transduced T cells control tumor growth in vivo.

IL6 mRNA is not detected in metastatic prostate cancer cells.

AXL is not expressed in human prostate tumors.

Matriptase-2 inhibited breast tumor development in vivo.

Ki-67 expression is determined by the cell-cycle stage.

Rapamycin decreases PD-L1 expression in lung tumors in vivo.

Histopathology of anal tissue.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

SAF-1 expression in clinical breast cancer tissues.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

PTEN expression regulates autophagy in tumor cells, reducing T cell–mediated killing. PTEN expression regulates autophagy in tumor cells, reducing T cell–mediated.

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

CD4+ and CD8+ TILs express surface CD137.

Expression pattern of TLR-4 and MyD88 in EOC cells.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

GM-CSF is required for CA-MSC–induced tumor metastasis.

SY-1425 induces maturation in RARA-high AML

Establishment of 12 PDX from BRAF inhibitor–progressed patients.

PD-L1 is expressed in breast cancer.

Reduced klotho expression in pancreatic cancer.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate distinct mechanisms of regulation. PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Reduced number and impaired effector functions of TILs in tumors with PTEN deletion or loss-of-function mutations in PTEN. Cutaneous melanoma patients.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

In vivo effects of TTFields on intradermal tumors in mice.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

BCMab1 confers Fc-FcγR–dependent antitumor activity through both macrophages and NK cells. BCMab1 confers Fc-FcγR–dependent antitumor activity through.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

In vivo shRNA screening in PDXs from 3 patients with melanoma.

Establishment and characterization of primary CAFs from patients with colorectal cancer. Establishment and characterization of primary CAFs from patients.

GCS-100 selectively kills KRAS-addicted lung tumors.

Validation of KMT2D function in MM23, MM2, and MM25 PDXs

AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. A,

PTEN genotype frequently dictates PTEN expression status, but evidence of heterogeneous staining implies polyclonality within some ovarian tumors. PTEN.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

GSN and DNMT1 expression are inversely correlated in a pattern associated with patient survival. GSN and DNMT1 expression are inversely correlated in a.

Presentation transcript:

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas. A, the PD-L1 surface expression levels in melanoma cells with and without PTEN silencing. A375 and WM35 tumor cells were transduced with control shRNA or PTEN-specific shRNA. Transduced tumor cells were stained with anti–PD-L1 to evaluate the surface expression of PD-L1. B, the in vivo PD-L1 expression in melanoma tumor tissues with and without PTEN silencing. B6 nude mice were challenged with A375/GH/shPTEN or A375/GH/shNS tumor cells. Tumor samples were collected from mice bearing 14-day established tumors. The PD-L1 mRNA expression levels in tumor samples were determined using real-time PCR. C, examples of IHC for PD-L1 in tumors with clonal PTEN expression. D, the PD-L1 surface expression levels in tumor samples from patients with stage IIIB/C melanoma. Tumor samples were placed in PTEN-absent and PTEN-present groups, and the expression of PD-L1 on the tumor surface was determined by IHC. Weiyi Peng et al. Cancer Discov 2016;6:202-216 ©2016 by American Association for Cancer Research